Dopamine D2 Receptor Radiopharmaceutical: I-123-Epidepride Toxicology and Preclinical SPECT Image

Shih-Ying Lee, Yuan-Ruei Huang, Jun-Ming Shih, Yu-Lung Wu, Chia-Chieh Chen, Kang-Wei Chang

Research output: Contribution to journalArticle

Abstract

Dopamine plays an important role in the brain, and several diseases of the central nervous system are associated with dopamine system dysfunction. A significantly different density of dopamine D2 receptors has been reported in Parkinson’s disease patients. Dopamine D2 receptor distribution in the central nervous system can be evaluated using the radiopharmaceutical [123I]Epidepride, which shows great potential for use as an imaging agent. In the image analysis software showed that the binding ratios of [123I]Epidepride significantly useful alterations of dopamine D2/D3 receptor binding sites in striatum, hypothalamus and midbrain. To investigate the toxicity of this radiopharmaceutical, we determined its effects in Sprague Dawley rats. We first synthesized Epidepride for the toxicity study, and then sought to determine the “No Observed Adverse Effect Level” (NOAEL) of Epidepride by analyzing acute single-dose effects. We injected unlabeled Epidepride (0 to 2000 µg/kg) into the tail vein of rats. This dose provided a safety margin of 100- to 10,000-fold over the maximum recommended human dose (200 µg/60 kg). After two weeks, we observed rat mortality, clinical situation (hypoactivity, body weight), and gross necropsy, and there were no changes. This lack of change showed that Epidepride exerted no adverse toxic effects in our rat model at dosage levels up to 2000 µg/kg. The results can achieve suitable be a reference method in toxicology and in vivo image for new drug studies of dopamine D2/D3 receptor related disease like schizophrenia and Parkinson’s syndrome to helpful evaluate therapeutic effects in the future.
Original languageTraditional Chinese
Pages (from-to)610-621
Number of pages7
JournalEC Pharmacology and Toxicology
Volume6
Issue number7
Publication statusPublished - Jul 1 2018
Externally publishedYes

Keywords

  • Epidepride
  • Toxicity
  • Parkinson’s Syndrome
  • SPECT/CT

Cite this

Dopamine D2 Receptor Radiopharmaceutical : I-123-Epidepride Toxicology and Preclinical SPECT Image. / Lee, Shih-Ying; Huang, Yuan-Ruei; Shih, Jun-Ming; Wu, Yu-Lung; Chen, Chia-Chieh; Chang, Kang-Wei.

In: EC Pharmacology and Toxicology, Vol. 6, No. 7, 01.07.2018, p. 610-621.

Research output: Contribution to journalArticle

Lee, Shih-Ying ; Huang, Yuan-Ruei ; Shih, Jun-Ming ; Wu, Yu-Lung ; Chen, Chia-Chieh ; Chang, Kang-Wei. / Dopamine D2 Receptor Radiopharmaceutical : I-123-Epidepride Toxicology and Preclinical SPECT Image. In: EC Pharmacology and Toxicology. 2018 ; Vol. 6, No. 7. pp. 610-621.
@article{afe7dcf4b5144985820f33c050b26866,
title = "Dopamine D2 Receptor Radiopharmaceutical: I-123-Epidepride Toxicology and Preclinical SPECT Image",
abstract = "Dopamine plays an important role in the brain, and several diseases of the central nervous system are associated with dopamine system dysfunction. A significantly different density of dopamine D2 receptors has been reported in Parkinson’s disease patients. Dopamine D2 receptor distribution in the central nervous system can be evaluated using the radiopharmaceutical [123I]Epidepride, which shows great potential for use as an imaging agent. In the image analysis software showed that the binding ratios of [123I]Epidepride significantly useful alterations of dopamine D2/D3 receptor binding sites in striatum, hypothalamus and midbrain. To investigate the toxicity of this radiopharmaceutical, we determined its effects in Sprague Dawley rats. We first synthesized Epidepride for the toxicity study, and then sought to determine the “No Observed Adverse Effect Level” (NOAEL) of Epidepride by analyzing acute single-dose effects. We injected unlabeled Epidepride (0 to 2000 µg/kg) into the tail vein of rats. This dose provided a safety margin of 100- to 10,000-fold over the maximum recommended human dose (200 µg/60 kg). After two weeks, we observed rat mortality, clinical situation (hypoactivity, body weight), and gross necropsy, and there were no changes. This lack of change showed that Epidepride exerted no adverse toxic effects in our rat model at dosage levels up to 2000 µg/kg. The results can achieve suitable be a reference method in toxicology and in vivo image for new drug studies of dopamine D2/D3 receptor related disease like schizophrenia and Parkinson’s syndrome to helpful evaluate therapeutic effects in the future.",
keywords = "Epidepride, Toxicity, Parkinson’s Syndrome, SPECT/CT",
author = "Shih-Ying Lee and Yuan-Ruei Huang and Jun-Ming Shih and Yu-Lung Wu and Chia-Chieh Chen and Kang-Wei Chang",
year = "2018",
month = "7",
day = "1",
language = "繁體中文",
volume = "6",
pages = "610--621",
journal = "EC Pharmacology and Toxicology",
number = "7",

}

TY - JOUR

T1 - Dopamine D2 Receptor Radiopharmaceutical

T2 - I-123-Epidepride Toxicology and Preclinical SPECT Image

AU - Lee, Shih-Ying

AU - Huang, Yuan-Ruei

AU - Shih, Jun-Ming

AU - Wu, Yu-Lung

AU - Chen, Chia-Chieh

AU - Chang, Kang-Wei

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Dopamine plays an important role in the brain, and several diseases of the central nervous system are associated with dopamine system dysfunction. A significantly different density of dopamine D2 receptors has been reported in Parkinson’s disease patients. Dopamine D2 receptor distribution in the central nervous system can be evaluated using the radiopharmaceutical [123I]Epidepride, which shows great potential for use as an imaging agent. In the image analysis software showed that the binding ratios of [123I]Epidepride significantly useful alterations of dopamine D2/D3 receptor binding sites in striatum, hypothalamus and midbrain. To investigate the toxicity of this radiopharmaceutical, we determined its effects in Sprague Dawley rats. We first synthesized Epidepride for the toxicity study, and then sought to determine the “No Observed Adverse Effect Level” (NOAEL) of Epidepride by analyzing acute single-dose effects. We injected unlabeled Epidepride (0 to 2000 µg/kg) into the tail vein of rats. This dose provided a safety margin of 100- to 10,000-fold over the maximum recommended human dose (200 µg/60 kg). After two weeks, we observed rat mortality, clinical situation (hypoactivity, body weight), and gross necropsy, and there were no changes. This lack of change showed that Epidepride exerted no adverse toxic effects in our rat model at dosage levels up to 2000 µg/kg. The results can achieve suitable be a reference method in toxicology and in vivo image for new drug studies of dopamine D2/D3 receptor related disease like schizophrenia and Parkinson’s syndrome to helpful evaluate therapeutic effects in the future.

AB - Dopamine plays an important role in the brain, and several diseases of the central nervous system are associated with dopamine system dysfunction. A significantly different density of dopamine D2 receptors has been reported in Parkinson’s disease patients. Dopamine D2 receptor distribution in the central nervous system can be evaluated using the radiopharmaceutical [123I]Epidepride, which shows great potential for use as an imaging agent. In the image analysis software showed that the binding ratios of [123I]Epidepride significantly useful alterations of dopamine D2/D3 receptor binding sites in striatum, hypothalamus and midbrain. To investigate the toxicity of this radiopharmaceutical, we determined its effects in Sprague Dawley rats. We first synthesized Epidepride for the toxicity study, and then sought to determine the “No Observed Adverse Effect Level” (NOAEL) of Epidepride by analyzing acute single-dose effects. We injected unlabeled Epidepride (0 to 2000 µg/kg) into the tail vein of rats. This dose provided a safety margin of 100- to 10,000-fold over the maximum recommended human dose (200 µg/60 kg). After two weeks, we observed rat mortality, clinical situation (hypoactivity, body weight), and gross necropsy, and there were no changes. This lack of change showed that Epidepride exerted no adverse toxic effects in our rat model at dosage levels up to 2000 µg/kg. The results can achieve suitable be a reference method in toxicology and in vivo image for new drug studies of dopamine D2/D3 receptor related disease like schizophrenia and Parkinson’s syndrome to helpful evaluate therapeutic effects in the future.

KW - Epidepride

KW - Toxicity

KW - Parkinson’s Syndrome

KW - SPECT/CT

M3 - 文章

VL - 6

SP - 610

EP - 621

JO - EC Pharmacology and Toxicology

JF - EC Pharmacology and Toxicology

IS - 7

ER -